Multiscale Model Identifies Improved Schedule for Treatment of Acute Myeloid Leukemia In Vitro With the Mcl‐1 Inhibitor AZD5991

Multiscale Model Identifies Improved Schedule for Treatment of Acute Myeloid Leukemia In Vitro With the Mcl‐1 Inhibitor AZD5991

Anticancer efficacy is driven not only by dose but also by frequency and duration of treatment. We describe a multiscale model combining cell cycle, cellular heterogeneity of B‐cell lymphoma 2 family proteins, and pharmacology of AZD5991, a potent small‐molecule inhibitor of myeloid cell leukemia 1...

Full description

Bibliographic Details
Main Authors: Ardeshir Goliaei, Haley A. Woods, Adriana E. Tron, Matthew A. Belmonte, J. Paul Secrist, Douglas Ferguson, Lisa Drew, Adrian J. Fretland, Bree B. Aldridge, Francis D. Gibbons
Format: Article
Language:English
Published: Wiley 2020-10-01
Series:CPT: Pharmacometrics & Systems Pharmacology
Online Access:https://doi.org/10.1002/psp4.12552

Internet

https://doi.org/10.1002/psp4.12552

Similar Items